Class of 2007: Joel Bathe

MBiotech Class of 2007: Joel Bathe
Senior Product Manager, InterMune Canada

InterMune Canada is the Canadian affiliate of InterMune, Inc., a biotechnology company focused on developing and commercializing innovative therapies in pulmonology and orphan fibrotic diseases. Research programs are focused on the discovery of targeted therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.

Joel’s first co-op placement from MBiotech program was with Genzyme Canada, a mid-size biotech focused on development and commercialization of treatments for ultra-orphan conditions.  He held various positions in marketing and became a product manager for an enzyme replacement therapy to treat mucopolysaccharidosis . After 7 years at Genzyme, he had the opportunity to move to InterMune and be a part of building an organization as well as launch the first treatment for another rare, life-threatening condition called Idiopathic pulmonary fibrosis.

Joel is also the President of the Ontario Pharmaceutical Marketing Association (OPMA). OPMA is an association built to address the need for pharmaceutical executives and suppliers to discuss issues affecting the pharmaceutical industry in Canada. It has provided an informal forum to network and an opportunity to socialize with peers over the last three decades.

Joel says that the MBiotech Program fostered a love of science and an appreciation for early stage research, two things that have helped him succeed in his career.